The most comprehensive study, published in BioMed Research International (2021), found that 5-amino-1MQ treatment "reverses diet-induced obesity and related T2D" in obese mice
You may also like Healing & Recovery ARA-290 16MG ARA-290 16mg (Cibinetide) Non-Erythropoietic EPO-Derived Research Peptide ARA-290 (Cibin Healing & Recovery BPC-157 10MG BPC-157 10MG Regenerative Peptide for Tissue Protection & tissue recovery processes BPC- Healing & Recovery BPC-157 5MG A 15-amino-acid partial sequence of Body Protection Compound, isolated from human gastric
Reproductive and developmental toxicity studies indicate no adverse effects on fertility, pregnancy outcomes, or offspring development in rodent models exposed to BPC-157
Felt normal and not fatigued for the first time in a very long time
Mechanistic Understanding Gaps Fundamental aspects of combination pharmacology require clarification[23]: Receptor-level interactions between components unknown (synergistic, additive, or antagonistic) Optimal dosing sequences and escalation protocols not scientifically established Tissue-specific distribution of combined formulation requires investigation Metabolic pathway interactions between incretin and amylin systems incompletely mapped Whether combination provides true synergy or simply additive effects remains unclear Population-Specific Considerations Research gaps exist for specific populations[24]: Renal impairment effects on peptide clearance inadequately studied Hepatic dysfunction impact on safety profile unclear Elderly populations (over 75 years) underrepresented in trials Racial and ethnic diversity in study populations limited Patients with cardiovascular disease require additional safety data Regulatory & Competitive Sport Status FDA Position Neither component has received FDA approval for any indication as of September 2025: GLP3 in phase 3 development for obesity and type 2 diabetes (TRIUMPH trials ongoing) Cagrilintide in phase 3 development as part of CagriSema combination Combined GLP3 + cagrilintide formulation not under regulatory review Not legally available for medical use, compounding, or human consumption No established therapeutic use basis for the combination Both peptides remain investigational drugs under active clinical development by their respective manufacturers
